Sumary of Novel treatment effective against overactive bladder in phase 2 study:
- September 10, 2021 2 min read Source/Disclosures Source: Son HS. MP02-18: Efficacy and Safety of DA8010, a novel M3 antagonist, in Patients with Overactive Bladder: Randomized, Double-blind, Phase 2 study.
- Back to Healio The novel muscarinic M3 receptor antagonist DA8010 significantly reduced urine frequency and urgency episodes compared with placebo in adults with overactive bladder, according to recent findings.
- Hee Seo Son, MD, PhD, of Yonsei University College of Medicine in South Korea, presented the study data at the virtual American Urological Association meeting.
- A novel treatment for overactive bladder was effective in a phase 2 trial, according to researchers.
- The researchers randomly assigned patients to receive one of four treatments: 2.5 mg of DA8010;
- The researchers evaluated DA8010 for its clinical efficacy, safety and optimal dosage.
- At 12 weeks, the mean values for 24-hour frequency were -1.01 in the placebo group, -1.22 in the DA8010 2.5-mg group, -1.56 in the solifenacin succinate group and -1.67 in the DA8010 5-mg group.
- The difference in mean frequency was insignificant in the DA8010 groups compared with the solifenacin succinate group.